Table 4 Current annual spending and potential for savings on drugs for the treatment of hypertension
|  | Current spending on thiazides* | Potential increased spending on thiazides†| Current spending on non-thiazides* | Potential decreased spending on non-thiazides‡ | Resulting potential savings (per inhabitant) |
|---|---|---|---|---|---|
Canada | $11.7 million | $1.4 million (12%) | $509.3 million | $15.2 million (3%) | $13.8 million ($0.44) |
France | $49.7 million | $95.8 million (193%) | $767.0 million | $133.2 million (17%) | $37.4 million ($0.63) |
Germany | $39.1 million | $42.0 million (107%) | $910.4 million | $114.1 million (13%) | $72.2 million ($0.87) |
Norway | $0.5 million | $1.4 million (282%) | $55.4 million | $12.1 million (22%) | $10.7 million ($2.40) |
UK | $35.3 million | $20.3 million (58%) | $643.3 million | $140.0 million (22%) | $119.7 million ($2.01) |
US | $238.1 million | $75.6 million (32%) | $7 709.8 million | $509.1 million (7%) | $433.6 million ($1.57) |